Date published: 2026-11-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

DR5 Antibody (MD5-1): sc-57086

4.0(1)
Write a reviewAsk a question
Datasheets
  • DR5 Antibody (MD5-1) is a Armenian hamster monoclonal IgG, cited in 2 publications, provided at 200 µg/ml
  • raised against DR5 of mouse origin
  • recommended for detection of DR5 of mouse origin by FCM
  • At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for DR5 Antibody (MD5-1). This work is in progress.
Gene Editing Promo Banner

QUICK LINKS

SEE ALSO...

DR5 Antibody (MD5-1) is a hamster monoclonal IgG antibody that detects DR5 in mouse samples through flow cytometry (FCM). DR5, also known as death receptor 5, is a crucial member of the tumor necrosis factor receptor superfamily and plays a significant role in mediating apoptosis, particularly in response to the cytokine TRAIL (TNF-related apoptosis-inducing ligand). Anti-DR5 antibody (MD5-1) recognizes a protein vital for regulating cell death and maintaining tissue homeostasis. When TRAIL binds to DR5, a cascade of intracellular signaling events leads to the recruitment of adaptor proteins and formation of the death-inducing signaling complex (DISC), ultimately resulting in apoptosis. This mechanism is particularly important in cancer biology, as many tumors exploit these pathways to evade programmed cell death, making DR5 a potential target for therapeutic interventions aimed at restoring apoptosis in cancer cells. DR5 (MD5-1) antibody serves as an essential tool for researchers studying these pathways and developing novel cancer treatments.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA

LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences

DR5 Antibody (MD5-1) References:

  1. Apoptosis. DR5 unfolds ER stress.  |  Zlotorynski, E. 2014. Nat Rev Mol Cell Biol. 15: 498-9. PMID: 25027654
  2. Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.  |  Mert, U. and Sanlioglu, AD. 2017. Cell Mol Life Sci. 74: 245-255. PMID: 27510421
  3. Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.  |  Dubuisson, A. and Micheau, O. 2017. Antibodies (Basel). 6: PMID: 31548531
  4. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.  |  van der Horst, HJ., et al. 2021. Blood Adv. 5: 2165-2172. PMID: 33885752
  5. Induction of DR5-Dependent Apoptosis by PGA2 through ATF4-CHOP Pathway.  |  Park, KM., et al. 2022. Molecules. 27: PMID: 35744931
  6. Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5.  |  Woo, SM., et al. 2022. Cell Death Dis. 13: 821. PMID: 36153316
  7. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.  |  Wang, L., et al. 2022. Nat Cancer. 3: 1284-1299. PMID: 36414711
  8. A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury.  |  Yang, C., et al. 2023. Nat Commun. 14: 4261. PMID: 37460623
  9. Glycyrrhetinic acid attenuates endoplasmic reticulum stress-induced hepatocyte apoptosis via CHOP/DR5/Caspase 8 pathway in cholestasis.  |  Zou, B., et al. 2023. Eur J Pharmacol. 961: 176193. PMID: 37981257
  10. ASB3 promotes hepatocellular carcinoma progression by mediating DR5 ubiquitination in TRAIL resistance.  |  Huang, L., et al. 2024. FASEB J. 38: e23475. PMID: 38334450

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

DR5 Antibody (MD5-1)

sc-57086
200 µg/ml
$322.00